1-13 of 13
Syed Abbas Ali
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Luciano J. Costa, Fredrik Schjesvold, Rakesh Popat, David Siegel, Saad Z. Usmani, Syed Abbas Ali, Michael P. Chu, Monique A. Hartley-Brown, Nizar J. Bahlis, Albert Oriol, Joaquín Martínez Lopez, Enrique M. Ocio, Karthik Ramasamy, Donna Reece, Emma Searle, Allison Gaudy, Antonina Kurtova, Wen Zhang, Rafael Sarmiento, August Dietrich, Jessica Katz, Michael Pourdehnad, Paul G. Richardson
Journal: Blood
Blood (2024) 144 (Supplement 1): 677.
https://doi.org/10.1182/blood-2024-198403
Published: 2024
Journal Articles

Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael H. Tomasson, Eli Gabayan, Syed Abbas Ali, Gabriel Afram, Sona Ghorashi, Trish Creel, Luisa Paccagnella, Carolyn Lou, Ola Landgren
Journal: Blood
Blood (2024) 144 (Supplement 1): 1024.
https://doi.org/10.1182/blood-2024-210520
Published: 2024
Journal Articles

Use of Baseline Inflammatory Markers to Predict Toxicities Among Relapsed/Refractory Multiple Myeloma Patients Receiving Ambulatory Teclistamab and Talquetamab

Nadeem Tabbara, Michael Singel, Natalie Allen, Audra Shedeck, Kathy Mooney, Kathryn Campion, Callan Raymond, Inna Sabirzhanova, Karen Anderson, Sarah Waheed, Carol Ann Huff, Syed Abbas Ali, Christian B. Gocke, Philip Imus
Journal: Blood
Blood (2024) 144 (Supplement 1): 7232.
https://doi.org/10.1182/blood-2024-210189
Published: 2024
Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Jonathan Allen Webster, Madison C Reed, Hua-Ling Tsai, Philip Imus, B. Douglas Smith, Alexander J. Ambinder, Mark J. Levis, Amy E. DeZern, Gabrielle T. Prince, Javier Bolanos-Meade, Lukasz P. Gondek, Gabriel Ghiaur, William Brian Dalton, Theodoros Karantanos, Suman Paul, Ephraim Joseph Fuchs, Cole Sterling, Lode J. Swinnen, Nina Wagner-Johnston, Richard F. Ambinder, Christian B. Gocke, Syed Abbas Ali, Carol Ann Huff, Leo Luznik, Ravi Varadhan, Richard J. Jones, Ivana Gojo
Journal: Blood
Blood (2024) 144 (Supplement 1): 3551.
https://doi.org/10.1182/blood-2024-212141
Published: 2024
Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik
Journal: Blood
Blood (2023) 142 (Supplement 1): 3473.
https://doi.org/10.1182/blood-2023-179394
Published: 2023
Journal Articles

CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity

Meisam Naeimi Kararoudi, Yuya Nagai, Ezgi Elmas, Marcelo de Souza Fernandes Pereira, Syed Abbas Ali, Philip Hollingsworth Imus, Darren Wethington, Ivan Marques Borrello, Dean Anthony Lee, Gabriel Ghiaur
Journal: Blood
Blood (2020) 136 (21): 2416–2427.
https://doi.org/10.1182/blood.2020006200
Published: 2020
Includes: Supplemental data
Journal Articles

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Luca Biavati, MD, Anna Ferguson, BSN, RN, Carol Ann Huff, MD, Lakshmi Rudraraju, MS, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Syed Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1895.
https://doi.org/10.1182/blood-2019-128430
Published: 2019
Journal Articles

CD38 Knockout Primary NK Cells to Prevent "Fratricide" and Boost Daratumumab Activity

Yuya Nagai, MD, Meisam Naeimi Kararoudi, PhD DVM, Ezgi Elmas, MS, Marcelo Pereira, Syed Abbas Ali, MD, Philip Hollingsworth Imus, MD, Dean Anthony Lee, MD PhD, Gabriel Ghiaur, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 870.
https://doi.org/10.1182/blood-2019-129456
Published: 2019
Journal Articles

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

My L Nguyen, PharmD, Catherine Burdalski, PharmD, BCOP, Syed Abbas Ali, MD, Lindsay Kohler, BS, PharmD Candidate, Steven Gilmore, PharmD, BCOP
Journal: Blood
Blood (2019) 134 (Supplement_1): 5811.
https://doi.org/10.1182/blood-2019-125391
Published: 2019
Journal Articles

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin L. Costello, MD, Tara K. Gregory, MD, Syed Abbas Ali, MD, Jesus G. Berdeja, MD, Krina K. Patel, MDMSc, Nina D. Shah, MD, Eric Ostertag, Chris Martin, Majid Ghoddusi, PhD DVM, Devon J Shedlock, PhD, Matthew A. Spear, MD, Robert Z. Orlowski, MD, PhD, Adam D. Cohen, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3184.
https://doi.org/10.1182/blood-2019-129562
Published: 2019
Journal Articles

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Tara Gregory, MD, Adam D. Cohen, MD, Caitlin L. Costello, MD, Syed Abbas Ali, MD, Jesus G. Berdeja, MD, Eric M Ostertag, MD PhD, Christopher Martin, PhD, Devon J Shedlock, PhD, Michelle Lynn Resler, BS, Matthew A. Spear, MD, Robert Z. Orlowski, MD PhD, Krina K. Patel, MDMSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2018-99-111419
Published: 2018
Journal Articles

T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Clinical Trials & Observations
Syed Abbas Ali, Victoria Shi, Irina Maric, Michael Wang, David F. Stroncek, Jeremy J. Rose, Jennifer N. Brudno, Maryalice Stetler-Stevenson, Steven A. Feldman, Brenna G. Hansen, Vicki S. Fellowes, Frances T. Hakim, Ronald E. Gress, James N. Kochenderfer
Journal: Blood
Blood (2016) 128 (13): 1688–1700.
https://doi.org/10.1182/blood-2016-04-711903
Published: 2016
Includes: Supplemental data
Journal Articles

Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor

Syed Abbas Ali, MD, Victoria Shi, Michael Wang, MD, David Stroncek, MD, Irina Maric, Jennifer N Brudno, MD, Maryalice Stetler-Stevenson, Jeremy J. Rose, BA, Steven Feldman, Brenna Hansen, Frances T. Hakim, PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD
Journal: Blood
Blood (2015) 126 (23): LBA-1.
https://doi.org/10.1182/blood.V126.23.LBA-1.LBA-1
Published: 2015